by zhaoq | Nov 19, 2025
Our center’s latest research has been published in Health Affairs, one of the world’s leading journals in health policy, widely recognized for its authority and high impact (2023 Impact Factor: 8.1). The article, titled “Follow-On Cancer Drugs Target Earlier Stages...
by deyuz | Sep 26, 2025
Abstract This policy brief evaluates the potential impact of Most Favored Nation (MFN) pricing on pharmaceutical innovation and patient health. We analyze MFN pricing being imposed in Medicare and Medicaid, requiring U.S. prices for already launched drugs to match the...
by zhaoq | Sep 25, 2025
Abstract Prescription drugs have drawn significant policy and public attention in discussions of rising health care costs in the United States. However, their actual contribution to the growth of total health care spending remains uncertain. Drawing on data from the...
by maica | Jun 9, 2025
This policy brief presents a quantitative analysis of the price of drug prescriptions filled in the United States compared to other developed nations. While past comparisons have often focused only on brand-name prescription prices, we evaluate the entire distribution...
by mheinl | Oct 3, 2023
This policy brief provides a quantitative analysis of how the Inflation Reduction Act’s (IRA) policy to set prices for select small molecule drugs 9 years after FDA approval impacts innovation and patient health. Price setting under the IRA undermines existing...
Scroll to Top
